



Oncology bulletin

October 2025

The aim of this current awareness bulletin is to provide a digest of recent guidelines, reports, research and best practice on Oncology

If you would like to request any of the articles included in this bulletin, or be put onto the distribution list, please contact: ulth.library.grantham@nhs.net

For more information on Library and Knowledge Services please go to:
www.nhslincslibrary.uk

Cancer Treatments

Personal View

Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials

Since the reform of China's drug review and approval in 2015, it has successfully stimulated the enthusiasm of domestic pharmaceutical companies to carry out innovative drug research and development, especially in oncology. Chinese pharmaceutical companies that developed cancer drugs have begun shifting from an in China, for China model to an in China, for global model given the constrained market share. However, many challenges are confronting Chinese pharmaceutical companies when entering overseas markets. Conducting multiregional clinical trials (MRCTs) has been widely regarded by the industry as a crucial step for innovative drugs to achieve overseas commercialisation.

Xin Du et al

Lancet Oncology 26 (10) e558-e569

General

Review

Clinical prediction models using machine learning in oncology: challenges and recommendations

Clinical prediction models are widely developed in the field of oncology, providing individualised risk estimates to aid diagnosis and prognosis. Machine learning methods are increasingly being used to develop prediction models, yet many suffer from methodological flaws limiting clinical implementation. This review outlines key considerations for developing robust, equitable prediction models in cancer care.

Gary S Collins et al

BMJ Oncology 4 e000914 (open access)

Specific Cancers



Technology appraisal guidance

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

NICE Guidance TA 1099

Technology appraisal guidance

Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

NICE Guidance TA 1103

Editorial

Understanding prostate cancer care: recent progress and future direction

Kristoffer Thomas Stewart et al

BMJ Oncology 4 e000985 (open access)

Research

Prostate specific antigen retesting intervals and trends in England: population based cohort study

Objective - To characterise the use of the prostate specific antigen (PSA) test in primary care in England.

Kiana K Collins et al

BMJ 391 (8473) e083800 (open access)

Practice

EASILY MISSED? HPV positive oropharyngeal cancer

Dominic McKenna et al

BMJ 391 (8473) e086142

Original research

Sensory neuropeptide CGRP and its co-receptor RAMP1 drive tumour cell growth in gastrointestinal cancers

Objective - The gastrointestinal (GI) tract is densely innervated, forming a critical network that secretes neuropeptides essential for gut function. Tumour cells are highly adaptive and exploit their microenvironment, including nerves, to support and accelerate growth. However, the mechanisms by which tumour cells interact with neuropeptides in human GI cancers remain poorly understood. We aimed to investigate the expression and function of the sensory neuropeptide calcitonin gene-related peptide (CGRP) and its receptor component, receptor activity-modifying protein 1 (RAMP1), and to elucidate novel mechanisms by which cancer cells exploit neuropeptides.

Pavitha Parathan et al

BMJ Oncology 4 e000842 (open access)



Survivorship

Review

Health-care transitions for young people living beyond childhood and adolescent cancer: recommendations from the EU-CAYAS-NET consortium

Childhood and adolescent cancer survivors (age at diagnosis: 0–21 years) face increased risk for long-term health complications and less favourable outcomes in terms of functioning and social participation. Moreover, they often experience inadequate health-care transitions to appropriate services after leaving paediatric or adolescent services, while the prevalence and severity of late effects increase as they become adults. To address transition challenges, we developed evidence-based recommendations as part of the European Network of Youth Cancer Survivors project with the goal to improve health-care transitions to both long-term survivorship and adult care, ensuring continuity and addressing survivors' unique needs.

Jikke Wams et al

Lancet Oncology 26 (10) e525-e536

Editorial

Understanding characteristics of contemporary cancer survival for modelling the cost-effectiveness of new interventions

Xuanqian Xie et al

BMJ Oncology 4 e000958 (open access)

Original Research

Impact of loneliness on cancer mortality: a systematic review and meta-analysis

Samantha Cheng et al

BMJ Oncology 4 e000840 (open access)